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Background/aim: In this study, the effects of resveratrol as a natural polyphenol compound, gemcitabine as an antimetabolite that
has nucleoside structure analogous to deoxycytidine, and para-aminophenol-derived paracetamol were investigated with single and
combined applications in monolayers of the MDAH-2774 human ovarian cancer cell line.
Materials and methods: Drugs were evaluated in cell culture with respect to cell proliferation, cell cytotoxicity (trypan blue dye
exclusion test), synthesis phase of cell cycle, and cell structure in 24, 48, 72, and 96 h.
Result: Resveratrol and gemcitabine diminished both cell proliferation and cell cycle synthesis phase indication in monolayer cell
cultures (P < 0.05). All combination groups showed similar effects that were mainly more effective in respect to single usage of resveratrol
and gemcitabine in monolayer cell cultures.
Conclusion: The effects of gemcitabine, resveratrol, and paracetamol were investigated in monolayers of the MDAH-2774 human
ovarian cancer cell line and a decrease in cell number in cell cycle synthesis phase, prevention of cell proliferation, and destruction of
cell structure were observed.
Key words: Ovarian cancer, gemcitabine, paracetamol, resveratrol

1. Introduction
Ovarian cancer is called ‘the silent killer’ because it does not
have any obvious symptoms such as fatigue, weight change,
abdominal distention, and pain. The lack of efficient and
early detection is the reason for its high mortality rate (1).
Ovarian cancer is the fourth leading cause of cancer death
in women and has the highest mortality rate among all
gynecological cancers. The lifetime risk of ovarian cancer
is one in 60 women in industrial countries, but it is less
common among Asian and African women. Similar to
other solid tumors, the growth and metastasis of ovarian
cancer requires a chain of events. These events include
deterioration of the intercellular structure, changes in
cellular adhesion, cell migration, invasion, multiplication,
and new blood vessel formation (2).
* Correspondence: sayla@medipol.edu.tr

Because of vague symptoms and inadequate screening
methods in the early stages of ovarian cancer, more than
60% of patients are diagnosed at an advanced stage (3).
Surgical and cytotoxic treatments often show limited
benefits. Thus, agents that sensitize ovarian cancer cells to
cytotoxic treatments have been investigated. For example,
gemcitabine is a pyrimidine analog of deoxycytidine. Its
anticancer effect results from preventing DNA synthesis
through inhibition of polymerase and ribonucleotide
reductase enzymes (4). Gemcitabine is one of the most
commonly used chemotherapeutic agents in epithelial
ovarian cancer (5). Gemcitabine increases the sensitivity
of tumor cells to chemotherapy and prolongs the duration
of inhibition of DNA synthesis (4). In non-small-cell lung
cancer, gemcitabine and the combination of etoposide and
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cisplatin show similar tumor inhibition efficacy. Twenty
percent of ovarian cancer patients with acquired resistance
to cisplatin respond to treatment with gemcitabine.
Paracetamol/acetaminophen
(N-acetyl-paraaminophenol) is used classically to relieve pain, fever, and
malaise (6,7). This drug has also been found to have some
beneficial effects against cancer. High-dose paracetamol
can enhance chemotherapy activity against different
cancer cells in vitro and in vivo (8–10).
Various natural and synthetic materials are used in
cancer therapy to inhibit cell proliferation and trigger
apoptosis. Resveratrol (trans-3,4’-trihydroxystillbene),
a naturally occurring polyphenolic antioxidant found
in grapes and red wine, elicits diverse biochemical
responses and shows antiaging, antiinflammatory, and
antiproliferative effects in several cell types (11,12). The
molecular mechanisms of resveratrol’s inhibitory effect on
cellular signaling pathways have been described previously
(13).
The aim of the current study is to evaluate the in vitro
effects of gemcitabine, paracetamol, and resveratrol alone
and in combination on the time- and dose-dependent
proliferation and survival of human ovarian carcinoma
cell line MDAH-2774.
2. Materials and methods
2.1. Cell culture conditions and reagents
Human MDAH-2774 ovarian carcinoma cells (CRL No:
10303; American Type Culture Collection, Manassas, VA,
USA) were cultured in RPMI-1640 medium (Biological
Industries, Beit Haemek, Israel) supplemented with 10%
heat-inactivated fetal calf serum (GIBCO, Invitrogen Co.,
Paisley, UK), 100 units/mL penicillin (Sigma Chemical
Co., St Louis, MO, USA), and 100 µg/mL streptomycin
(Sigma Chemical Co.). Semiconfluent cells were harvested
from flasks using 0.05% trypsin (Sigma Chemical
Co.), following the addition of RPMI-1640 for trypsin
inactivation, and resuspended in culture medium.
2.2. IC50 and cytotoxicity
MDAH-2774 cells were seeded (5 × 105 cells/well) in
six-well plates and cultured for 24, 48, 72, or 96 h in the
presence of gemcitabine at 0.1, 1, 10, and 100 µg/mL and
resveratrol at 0.1, 1, 10, and 100 µM in 5 mL of media.
Paracetamol was added at 40 µg/mL. At the end of each
culturing period, cells were trypsinized (0.05%) and
centrifuged at 1500 rpm. Cell viability was determined by
the trypan blue exclusion assay. Cells (5 × 105 cells/well
with 100% vitality) were then plated in six-well culture
plates containing 5 mL of RPMI-1640 medium. The
concentrations of each drug required for 50% inhibition
(IC50) at 96 h were 10 µg/mL for gemcitabine, 10 µM for
resveratrol, and 40 µg/ml for paracetamol.
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MDAH-2774 cells were seeded at 5 × 105 cells/well in
six-well plates and treated with gemcitabine (10 µg/mL),
resveratrol (10 µM), paracetamol (40 µg/mL), gemcitabine
+ resveratrol (10 µg/mL + 10 µM), or gemcitabine +
paracetamol (10 µg/mL + 40 µg/mL) for 24, 48, 72, and
96 h. A buffer-treated control group was also included.
At each time point, cells were harvested and counted. The
number of dead cells was assessed using the trypan blue
exclusion assay.
2.3. Immunocytochemistry and cell proliferation
MDAH-2774 cells (1 × 105 cells/well) were seeded on
cover slips in 24-well plates. After 2 h, cells were treated
with 10 µM resveratrol, 10 µg/mL gemcitabine, 40 µg/mL
paracetamol, gemcitabine + resveratrol (10 µg/mL +10
µM), or gemcitabine + paracetamol (10 µg/mL + 40 µg/
ml). After 24, 48, 72, and 96 h, the cells were incubated
with BrdU at 37 °C for 1 h and then in PBS for 15 min.
Cells were fixed in 70% ethanol at –20 °C for 30 min and
then prepared for analysis.
Cells were rehydrated for 10 min in PBS and then
incubated in 0.5% H2O2 in methanol for 20 min in the
dark. A 4 N HCl solution was then applied to the samples
for 30 min and the cells were rinsed with distilled water,
followed by three washes with PBS. After blocking 15 min
in Ultra-V-Block (Thermo Fisher Scientific, Marietta, OH,
USA), coverslips were incubated with a primary antibody
solution (NCL-BrdU mouse monoclonal 1:100, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 1 h in a humidified
environment at room temperature. After rinsing with PBS,
a secondary antibody solution (Santa Cruz Biotechnology)
was applied for 30 min. The samples were rinsed with PBS
and incubated with streptavidin peroxidase for 30 min in
a humidified environment. Coverslips were then rinsed
with PBS, incubated in substrate-chromogen (AEC) for 20
min, and washed with distilled water. Cells were stained
with Mayer’s hematoxylin (Sigma Chemical Co.) and the
coverslips were mounted (Ultramount, Dako, Carpinteria,
CA, USA) on slides.
2.4. Electron microscopy
MDAH-2774 cells (1 × 105 cells/well) were seeded on
coverslips in 24-well plates. After 2 h, cells were treated
with 10 µM resveratrol, 10 µg/mL gemcitabine, 40 µg/
mL paracetamol, gemcitabine + resveratrol (10 µg/mL +
10 µM), or gemcitabine + paracetamol (10 µg/mL + 40
µg/mL) in 1 mL. The drugs were removed after 24 or 96
h, and a 2.5% glutaraldehyde solution was added. After
incubation for 30 min at 4 °C, samples were washed
twice with phosphate solution and incubated in 0.5 mL
of osmium tetroxide for 60 min. This was followed by
another wash with phosphate solution. Cells were then
successively incubated in 30%, 50%, 70%, and 90% ethanol
for 10 min each. This was followed by two incubations of
10 min each in 100% ethanol. Cells were next incubated
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successively for 10 min in a solution of 1:3 amyl acetate/
alcohol, 1:1 amyl acetate/alcohol, 3:1 amyl acetate/alcohol,
and 100% amyl acetate for 1 h. Coverslips were air-dried
at room temperature and cells were visualized using a JMS
5200 scanning electron microscope (JEOL, Peabody, MA,
USA).
2.5. Statistical analysis
SPSS 10.0 was used for all analyses. Because the data did
not show a homogeneous distribution, the nonparametric
Kruskal–Wallis test was used to calculate significance
between more than two independent groups. Further
analysis of the significant groups was performed using the
Mann–Whitney U test. P < 0.05 was considered significant.
3. Results
3.1. Cell proliferation
To study the effect of different types of drug treatments
on the number of viable ovarian cancer cells, MDAH2774 cells were treated with resveratrol, paracetamol,
gemcitabine, gemcitabine + paracetamol, or gemcitabine
+ resveratrol for 24, 48, 72, or 96 h and then stained with
trypan blue. As expected, the total number of MDAH-2774
cells increased with time. As shown in Figure 1, treatment
with resveratrol or paracetamol alone had no effect on
cell proliferation within the first 24 h (P > 0.05), but it
decreased cell proliferation at the later time points when
compared to the control group (P < 0.05). Treatment with
gemcitabine alone significantly inhibited cell proliferation
at each time point when compared to the control group
(P < 0.05). Treatment with gemcitabine + paracetamol, or
gemcitabine + resveratrol also significantly inhibited cell

proliferation at each time point when compared to the
control group (P < 0.05) (Figure 1).
3.2. Cytotoxicity data
MDAH-2774 cells treated with resveratrol, paracetamol,
gemcitabine, gemcitabine + paracetamol, or gemcitabine
+ resveratrol for 24, 48, 72, or 96 h were stained with
trypan blue to evaluate the effects of the drug treatments
on viability. In the first 24 h of treatment, none of the
drugs applied alone or in combination induced significant
cell death (P > 0.05) (Figure 2). However, significantly
fewer viable cells (unstained cells) were detected after
48, 72, and 96 h in all treatment groups compared to the
control. Gemcitabine, applied alone or in combination with
resveratrol or paracetamol, caused the greatest cytotoxicity
(P < 0.05) (Figure 2).
3.3. BrdU labeling index
To understand more precisely the effect of the different drug
treatments, proliferating MDAH-2774 cells on coverslips
were treated with resveratrol, paracetamol, gemcitabine,
gemcitabine + paracetamol, or gemcitabine + resveratrol
for 24, 48, 72, or 96 h and stained with BrdU (Figures
3a–3l). As expected, many cells in the control group were
in the active DNA synthesis phase (BrdU-positive cells)
(Figures 3a and 3g). Resveratrol treatment had a small effect
(P > 0.05) on proliferation in the first 24 h followed by a
significant decrease of the BrdU labeling index (BrdU-LI)
at 48, 72, and 96 h (P < 0.05) compared to the control group
(Figures 3b, 3h, and 4). Interestingly, in samples treated with
paracetamol, the BrdU-LI percentage was significantly lower
than in the control group (P < 0.05) only at 24 h, while it was
higher at the remaining time points (Figures 3c, 3i, and 4).

Figure 1: Cell proliferation (C: control, R: resveratrol, P: paracetamol, G: gemcitabine, R
+ G: resveratrol + gemcitabine, P + G: paracetamol + gemcitabine). Data are expressed
as mean ± SD.
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Figure 2: Cytotoxicity (viability) (C: control, R: resveratrol, P: paracetamol, G:
gemcitabine, G + R: resveratrol + gemcitabine, P + G: paracetamol + gemcitabine).
Data are expressed as mean ± SD.

Figure 3. Immunocytochemistry (BrDU). All at magnification of 40×. a–f: 24 h; g–l: 96 h; a: 24 h control group, where a large number of
MDAH-2774 ovary tumor cells marked with BrDU (red color) were observed (unmarked cells are blue); b: resveratrol; c: paracetamol;
d: gemcitabine, with fewer marked cells than the control; e: resveratrol + gemcitabine; f: paracetamol + gemcitabine; g: 96 h control
group, where results are similar to those of the 24 h control group; h: resveratrol, with fewer marked cells than at 24 h; i: paracetamol;
j: gemcitabine, with fewer marked cells than the control group; k: resveratrol + gemcitabine, with fewer marked cells than the control
group; l: paracetamol + gemcitabine.

Incubation of MDAH-2774 cells with gemcitabine
(Figures 3d and 3j), alone or in combination with
resveratrol (Figures 3e and 3k) or paracetamol (Figures
3f and 3l), strongly inhibited cell proliferation at all time
points when compared to the control group (P < 0.05)
(Figure 4).
3.4. Effect of different drug treatments on cell morphology
MDAH-2774 cells treated with resveratrol, paracetamol,
gemcitabine, gemcitabine + paracetamol, or gemcitabine
+ resveratrol were collected after 24 or 96 h and processed
for scanning electron microscopy (Figures 5a–5l). At 96
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h, the cells in the control group appeared healthy, many of
them in mitosis, with a flat shape and exhibiting normal
interactions with neighboring cells. Intact membranes
with long thin cytoplasmic extensions and microvilli
were observed (Figures 5a and 5g). Cells treated with
resveratrol for 24 h were morphologically similar to those
in the control group but showed a decreased number of
cytoplasmic extensions. Additionally, many cells were
blocked in mitosis. After 96 h, cells treated with resveratrol
were loosely attached with a preapoptotic appearance
(Figures 5b and 5h). In the paracetamol treatment group,
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Figure 4: BrDU labeling index (C: control, R: resveratrol, P: paracetamol, G: gemcitabine, G + R:
resveratrol + gemcitabine, P + G: paracetamol + gemcitabine). Data are expressed as mean ± SD.

Figure 5. Scanning electron microscopy. All magnification except that of k is 750×. a–f: 24 h; g–l: 96 h; a: 24 h control group; b: resveratrol;
c: paracetamol; d: gemcitabine; e: resveratrol + gemcitabine; f: paracetamol + gemcitabine; g: 96 h control group; h: resveratrol, where
degenerated tumor cells with a round appearance are evident; i: paracetamol tumor cells appear more degenerated compared to 24 h; j:
gemcitabine, where tumor cells are more damaged compared to 24 h; k: resveratrol + gemcitabine, where damaged and rounded cells
are evident, 1000×; l: paracetamol + gemcitabine, where damaged, rounded, and apoptotic cells are evident.

cells showed an apoptotic phenotype that was especially
evident at 96 h (Figures 5c and 5j). Treatment with
gemcitabine alone disrupted the cell morphology with a
loss of cytoplasmic extensions and dull villi. This phenotype
was particularly evident at 96 h. Cells also presented
membrane blebbing, a sign of apoptosis (Figures 5d and
5j). Combination treatment of resveratrol and gemcitabine
caused the loss of cellular cytoplasmic extensions and a
transition to a prespheroid shape at 24 h. At 96 h, more
round and aggregated cells, loosely attached to the surface
and without cytoplasmic extensions, were observed. In
addition, compared to the control group, many fewer
mitotic cells were recorded (Figures 5e and 5k). In the cells
treated with paracetamol and gemcitabine, major changes
were observed in the cell morphology. The vast majority of

the cells had lost their microvilli and the connections with
other cells were decreased. The number of apoptotic cells
was higher than in the control group (Figures 5f and 5l).
In summary, all treatments caused a loss of cytoplasmic
extensions, a decrease in mitotic cells, and an increase in
apoptotic cells.
4. Discussion
The use of natural products including medicinal plants
has become more and more important in primary
health care especially in developing countries. Many
pharmacognostical and pharmacological investigations
are carried out to identify new drugs or to find new lead
structures to develop novel therapeutic agents for the
treatment of human diseases such as cancer (14).

445

AYLA et al. / Turk J Med Sci
Our results show that treatment of MDAH-2774 cells
with resveratrol, paracetamol, and gemcitabine, separately
or in combination, significantly inhibited cell proliferation
at all the considered time points, although to a lesser extent
in the first 24 h. In addition, all treatments, applied alone
or in combination, induced significant cell death at 48, 72,
and 96 h, with gemcitabine showing the strongest effect
either alone or combined with resveratrol or paracetamol.
Recent studies have shown that agents like resveratrol,
found in high concentrations in grape seeds and skin and
well known for its antioxidant properties, may contribute
to cancer prevention (15). It was shown that grape seed
extract and resveratrol at concentrations of 1 to 100 µM
have varying degrees of cytotoxic and proapoptotic activity
in several cancer cell lines (15). Other researchers showed
that resveratrol may decrease the proliferation of tumor
cells by inducing apoptosis (16–18).
In the current study, we showed that 10 µM resveratrol
significantly inhibited the proliferation of MDAH-2774
cells and induced death at all time points tested. Inside a cell,
resveratrol prevents the activation of cyclooxygenase-1,
cyclooxygenase-2, and NF-κB while activating p53, bax,
and caspase (13). NF-κB, a transcription factor involved
in the regulation of responses to different stimuli, also
regulates cell proliferation and survival (19,20), linking
it to cancer development. The inhibition of NF-κB by
resveratrol has been described in many cancer cell lineages
such as epithelial (HeLa), lymphoid (Jurkat), and myeloid
(U937) (12,21,22). In this study, we showed that resveratrol
also inhibited the proliferation of MDAH-2774 ovarian
cancer cells.
In a randomized study comparing the effects of
5-fluorouracil and gemcitabine treatments on the 5-year
survival of pancreatic cancer patients, the latter drug,
which prevents DNA replication and repair, increased the
rate of survival with the induction of fewer side effects.
Furthermore, gemcitabine increased the sensitivity of
tumor cells to radiotherapy and, when used in combination
with radiotherapy, prolonged the inhibition of DNA
synthesis. Therefore, it has been suggested that gemcitabine
should be used as a first-line treatment of pancreatic cancer
(23). In our study, gemcitabine was a highly effective drug
against MDAH-2774 ovarian tumor cells, as shown by
inducing significantly lower proliferation, BrdU labeling,
and viability. This is consistent with previous reports
in other tumor models (24). Gemcitabine treatment
significantly reduced cell proliferation and decreased
the BrdU-LI at 24 and 48 h. At later time points (72 and
96 h), while significantly inhibiting cell proliferation,
gemcitabine increased the number of cells in the S-phase
(BrdU-positive). It has been observed in breast cancer
that a heterogeneous population of tumor cells is formed
due to rapid cell cycling and cell variability (10). Some of
these cells are sensitive to gemcitabine and will die. Others
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are resistant and, with time, begin to cycle, divide, and
proliferate.
Several molecular mechanisms have been suggested
to explain why paracetamol has inhibitory effects on the
growth of ovarian cancer. In cells, paracetamol is converted
to N-acetyl-p-benzoquinone (NAPQ1) by P450, which is
then detoxified by conjugation with glutathione (GSH). This
eliminates a thiol redox control mechanism essential for
the survival of ovarian tumor cells. Once GSH is depleted,
NAPQ1 can damage essential cellular proteins including
Ca+2-ATPase on the nuclear membrane. This is followed by
accumulation of Ca+2 in the nuclei, mitochondrial oxidative
stress, caspase-3-independent DNA fragmentation, and
cell death (25,26). In addition, the paracetamol-glutathione
conjugate inhibits the activity of glutathione S-transferase,
an enzyme that participates in the mechanism of resistance
to some anticancer drugs such as cisplatin and carboplatin.
This effect is consistent with the results of a study by Bilir et
al., who reported that paracetamol increased the sensitivity
of MDAH-2774 human ovarian cancer cells to carboplatin
(9) .
In the current study, a very strong effect was recorded
in the combination treatment group for resveratrol +
gemcitabine or paracetamol + gemcitabine, starting after 72
h. Treatment of MDAH-2774 cells with these combinations
caused a significant decrease in both cell proliferation and
the BrdU-LI, as well as a strong increase in cytotoxicity. This
was a result of paracetamol sensitizing cells to gemcitabine
treatment. Paracetamol alone promoted the proliferation
of MDAH-2774 cells, as evidenced by a higher number of
cells in the S-phase and a higher BrdU-LI. This suggests
that the increased sensitivity of these cells to gemcitabine,
which acts by binding to newly synthetized DNA, could be
promoted by paracetamol-induced cell proliferation.
As an alternative mechanism, the combination of
gemcitabine and paracetamol could act by increasing the
number of apoptotic cells and accelerating the apoptosis
rate. Our data suggest that the high cytotoxicity in the
resveratrol + gemcitabine and paracetamol + gemcitabine
groups is most likely mediated by this mechanism. In both
combination treatment groups, there was only a slight
increase in cytotoxicity at 96 h compared to the previous
time point. The effect of the combination of paracetamol
and gemcitabine on inhibiting DNA synthesis, particularly
at 72 and 96 h, was stronger than the effect of gemcitabine
alone.
Despite the efficacy of standard chemotherapy drugs,
tumors often relapse and show resistance to new therapeutic
approaches. This multiple drug resistance effect may be due
to a decrease in intracellular drug accumulation (due to
lower penetration of drugs into the cells or higher extrusion
of drugs from the cells), a lower ability of the drug to reach
its target, an increase in the cells detoxification ability, or a
change in drug distribution (27).
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Many mechanisms responsible for drug resistance in
tumors have been identified. In 1976, P-glycoprotein (P-gp),
a 170-kDa cell membrane protein, was identified as being
responsible for a decrease in the intracellular accumulation
of many drugs (27). A study by Draper et al. showed that
the development of resistance through P-gp activity could
be inhibited by NSAIDs such as indomethacin (27). In
our study, we showed that paracetamol + gemcitabine and
resveratrol + gemcitabine significantly decreased both cell
proliferation and the BrdU-LI, as well as increased cell
cytotoxicity.

Despite increasing knowledge of the molecular
mechanisms driving tumor development, cancer
remains a deadly disease. For this reason, continued
investigations into the processes regulating cancer
formation and progression are of great importance. A
deeper understanding of tumor biology is the basis for
developing more advanced diagnostic approaches and
effective treatments.
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